Evaluation of CA19.9 tumor marker in early diagnosis of pancreatic cancer by Chemi Luminescencent immunoassay method Evaluation of CA19.9 tumor marker
Journal of Behdasht dar Arseh (i.e., Health in the Field),
Vol. 11 No. 1 (1402),
5 Shahrivar 2023
,
Page 60-68
https://doi.org/10.22037/jhf.v11i1.41588
Abstract
Background and Aims: Evaluation of CA19-9 tumor marker level as a suitable and specific marker is useful in early diagnosis and clinical management of pancreatic malignancies with new and reliable laboratory methods such as quantitative luminescence method.
Objective: The present study was conducted with the aim of evaluating the serum level of CA 19-9 by quantitative luminescence method for the early diagnosis of PADC from other benign pancreatic diseases.
Materials and Methods: 150 serum samples including; 50 samples with PDAC in different stages of the disease, 50 samples with benign disease conditions (chronic pancreatitis) and 50 healthy samples were examined as reference and control groups based on age/sex. Data analysis was done using Spss version 18 in separate groups with logistic regression analysis, comparison of means (ANOVA) and Tukey.
Results: The three studied groups (healthy people with an average of 8.031, people with chronic pancreatitis with an average of 49.932, and people with pancreatic cancer with an average of 543.164 (F=231.652, P<0.0001) in terms of average statistical analysis The averages were completely different.90% of the patients were over 50 years old and there was a significant relationship between increasing age and increasing tumor marker CA19-9 (r=0.465, n=150, P=0.000).There was a weak significant relationship between the increase in CA19-9 tumor marker levels in men compared to women (r=0.166, n=150, P=0.042) and in men there was a significant increase in CA19-9 tumor marker levels (30 out of 50 people Patients with pancreatic cancer: 60%) were seen. Also, differentiation of chronic pancreatitis patients from pancreatic cancer with ROC statistical analysis at the cut-off point at 100 units/ml had 100% accuracy in identifying malignancy.
Conclusion: The level of tumor marker CA 19-9, using age and gender factors, significantly distinguished healthy people from those with chronic pancreatitis and pancreatic cancer with very appropriate accuracy.
- Pancreatic cancer, CA19-9 Tumormarker, Chemi Luminescencent immunoassay, Age and Gender.
How to Cite
References
2. Turpin, A., et al., Therapeutic advances in metastatic pancreatic cancer: A focus on targeted therapies. Therapeutic Advances in Medical Oncology, 2022. 14: p. 17588359221118019.
3. McGuigan, A., et al., Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World journal of gastroenterology, 2018. 24(43): p. 4846.
4. McGuigan, A.J., et al., Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta‐analysis. The Journal of Pathology: Clinical Research, 2021. 7(2): p. 99-112.
5. Pekgöz, M., Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment. World Journal of Gastroenterology, 2019. 25(29): p. 4019.
6. Mukherjee, S., et al., Radiomics-based machine-learning models can detect pancreatic cancer on prediagnostic computed tomography scans at a substantial lead time before clinical diagnosis. Gastroenterology, 2022. 163(5): p. 1435-1446. e3.
7. Resovi, A., et al., Soluble stroma‐related biomarkers of pancreatic cancer. EMBO molecular medicine, 2018. 10(8): p. e8741.
8. Fahrmann, J.F., et al., Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Gastroenterology, 2021. 160(4): p. 1373-1383. e6.
9. Ballehaninna, U.K. and R.S. Chamberlain, Serum CA 19-9 as a biomarker for pancreatic cancer—a comprehensive review. Indian journal of surgical oncology, 2011. 2: p. 88-100.
10. Lee, T., T.Z.J. Teng, and V.G. Shelat, Carbohydrate antigen 19-9—Tumor marker: Past, present, and future. World Journal of Gastrointestinal Surgery, 2020. 12(12): p. 468.
11. Feng, M., et al., Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis. International journal of clinical oncology, 2017. 22: p. 283-290.
12. Ardeshna, D.R., et al., Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes. Biomedicines, 2022. 10(7): p. 1475.
13. Honda, K., Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms. Cancer Biomarkers, 2022. 33(4): p. 503-512.
14. Jenkinson, C., et al., Biomarkers for early diagnosis of pancreatic cancer. Expert review of gastroenterology & hepatology, 2015. 9(3): p. 305-315.
15. O'Brien, D.P., et al., Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease DetectionEarly Detection of Pancreatic Cancer. Clinical Cancer Research, 2015. 21(3): p. 622-631.
16. Kim, M., et al., Prognostic value of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in gallbladder cancer; 65 IU/ml of CA 19-9 is the new cut-off value for prognosis. Cancers, 2021. 13(5): p. 1089.
17. Ballehaninna, U.K. and R.S. Chamberlain, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol, 2012. 3(2): p. 105-119.
18. Zhou, G., et al., Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. OncoTargets and therapy, 2017. 10: p. 1199.
19. Rychlíková, J., et al., Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomarkers, 2016. 17(1): p. 55-65.
- Abstract Viewed: 103 times
- PDF (فارسی) Downloaded: 70 times